Canadian #Cannabis Stock News: Emerald Health
(TSX VENTURE: $EMH) Announces Increase in Bought Deal to $24.4 Million
VICTORIA, BRITISH COLUMBIA - April 11, 2017 (Investorideas.com
Newswire) NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES .Emerald Health Therapeutics Inc. (TSX
VENTURE:EMH) ("Emerald" or the "Company") is pleased to
announce that it has entered into an amended letter of engagement with Eight
Capital (the "Underwriter") under which the Underwriter has now
agreed to purchase 13,170,000 units of the Company (the "Units"), on
a "bought deal" basis pursuant to the filing of a shelf prospectus
supplement, subject to all required regulatory approvals, at a price per Unit
of $1.85 (the "Offering Price"), for total gross proceeds of
$24,364,500 (the "Offering").
Each Unit shall consist of one common share of the Company (a
"Share") and one-half of one common share purchase warrant (each full
warrant, a "Warrant"). Each Warrant shall entitle the holder thereof
to acquire one Share at a price of $2.60 for a period of 24 months following
the Closing Date. In the event that the closing sale price of the Company's
Shares on the TSX Venture Exchange is greater than $3.50 per Share for a period
of 20 consecutive trading days at any time after the closing of the Offering,
the Company may accelerate the expiry date of the Warrants by giving notice to
the holders thereof and in such case the Warrants will expire on the 30th day
after the date on which such notice is given by the Company.
The Company has agreed to grant the Underwriter an
over-allotment option to purchase up to an additional 1,975,500 Units at the
Offering Price, exercisable in whole or in part, at any time on or prior to the
date that is 30 days following the closing of the Offering. If this option is
exercised in full, an additional $3,654,675 will be raised pursuant to the
Offering and the aggregate proceeds of the Offering will be $28,019,175.
The Company intends to use the net proceeds of the Offering to
accelerate facility expansion and for working capital and general corporate
purposes.
The Units will be offered by way of a shelf prospectus
supplement to be filed in all of the provinces of Canada, except Quebec,
pursuant to National Instrument 44-101 - Short Form Prospectus Distributions.
The closing date of the Offering is scheduled to be on or about
April 20, 2017 and is subject to certain conditions including, but not limited
to, the receipt of all necessary approvals, including the approval of the TSX
Venture Exchange and the applicable securities regulatory authorities.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of the securities
in any State in which such offer, solicitation or sale would be unlawful. The
securities being offered have not been, nor will they be, registered under the
United States Securities Act of 1933, as amended, and may not be offered or
sold in the United States absent registration or an applicable exemption from the
registration requirements of the United States Securities Act of 1933, as
amended, and applicable state securities laws.
Join us on our journey of enhancing health through cannabis
science.
For more information, explore our website and investor presentation
at emeraldhealth.ca.
Emerald
Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. operates primarily through
Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned
subsidiary of the Company and a Licensed Producer under the Access to Cannabis
for Medical Purposes Regulations (the "ACMPR"). Botanicals is
authorized to cultivate and sell both dried medical cannabis flowers and
medical cannabis oils in Canada. Botanicals currently operates an indoor cultivation
facility in Victoria, British Columbia, and plans to construct a much larger
purpose built hybrid greenhouse facility on 32 acres in metro Vancouver.
Botanicals prides itself on being one of Canada's most medically focused
licensed producers and on having one of the industry's most qualified
management teams with respect to pharmaceutical drug discovery, development and
distribution. Botanicals intends to capture unique niches in both the medical
and future adult use cannabis markets through its proprietary strains,
defensible intellectual property, and superb client experience.
Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable securities laws.
All statements that are not historical facts, including without limitation,
statements regarding future estimates, plans, programs, forecasts, projections,
objectives, assumptions, expectations or beliefs of future performance, are "forward-looking
statements".
We caution you that such "forward-looking statements"
involve known and unknown risks and uncertainties that could cause actual and
future events to differ materially from those anticipated in such statements.
Forward-looking statements include, but are not limited to, the filing and
effectiveness of the prospectus supplement; the use of proceeds from the
Offering; and the anticipated closing date of the Offering.
Emerald Health Therapeutics Inc. does not intend, and does not
assume any obligation, to update these forward-looking statements except as
required by law. These forward-looking statements involve risks and
uncertainties relating to, among other things, uncertainty with respect to the
completion of the Offering; the ability to obtain applicable regulatory
approval for the Offering; the ability of the Company to negotiate and complete
future funding transactions; variations in market conditions; and other risk
factors described in the Prospectus and the Company's other filings with the
applicable Canadian securities regulators, which may be viewed at
www.sedar.com. Actual results may differ materially from those expressed or
implied by such forward-looking statements.
"Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release."
Contact:
Emerald Health Therapeutics Inc.
Sandy Pratt
250-818-9838
invest@emerald.care
Sandy Pratt
250-818-9838
invest@emerald.care
Watch the 420
Cannabis Investor video
More Info:
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
No comments:
Post a Comment